Ryosuke Oki

Tokushima, 7700042, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

An R83W mutation in Rab3A causes autosomal-dominant cerebellar ataxia.

An R83W mutation in Rab3A causes autosomal-dominant cerebellar ataxia.

Journal: Human molecular genetics

Published: July 15, 2025

Evaluation of the diagnostic performance of brachial plexus ultrasound in amyotrophic lateral sclerosis.

Evaluation of the diagnostic performance of brachial plexus ultrasound in amyotrophic lateral sclerosis.

Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

Published: March 04, 2025

Ultra-high dose methylcobalamin and other emerging therapies for amyotrophic lateral sclerosis.

Ultra-high dose methylcobalamin and other emerging therapies for amyotrophic lateral sclerosis.

Journal: Current opinion in neurology

Published: July 31, 2024

An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study.

An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study.

Journal: JMIR research protocols

Published: August 24, 2022

Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.

Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.

Journal: EClinicalMedicine

Published: August 05, 2022

Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

Journal: JAMA neurology

Published: May 09, 2022

Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.

Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.

Journal: BMJ open

Published: December 05, 2019

JETALS: The Japanese Early-stage Trial of high dose methylcobalamin for ALS

JETALS: The Japanese Early-stage Trial of high dose methylcobalamin for ALS

Journal: Brain and nerve = Shinkei kenkyu no shinpo

Published: November 14, 2019

Differences in the intra-cerebellar connections and graph theoretical measures between Parkinson's disease and multiple system atrophy.

Differences in the intra-cerebellar connections and graph theoretical measures between Parkinson's disease and multiple system atrophy.

Journal: Journal of the neurological sciences

Published: December 10, 2018

The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial.

The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial.

Journal: JMIR research protocols

Published: September 10, 2018

Phenotype variability and allelic heterogeneity in KMT2B-Associated disease.

Phenotype variability and allelic heterogeneity in KMT2B-Associated disease.

Journal: Parkinsonism & related disorders

Published: December 05, 2017

A novel compound heterozygous TH mutation in a Japanese case of dopa-responsive dystonia with mild clinical course.

A novel compound heterozygous TH mutation in a Japanese case of dopa-responsive dystonia with mild clinical course.

Journal: Parkinsonism & related disorders

Published: July 25, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026